Antengene to Release Preliminary Results of Selinexor for the Treatment of Peripheral T-Cell Lymphoma and NK/T-Cell Lymphoma at the 2021 ASH Annual Meeting
SHANGHAI and HONG KONG, Nov. 9, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced the acceptance of an abstract at the upcoming 2021 American Society of Hematology (ASH) Annual...
InnoRNA of China participates in the Hanmi Science Consortium …”To join forces to eliminate ‘vaccine divide'”
SEOUL, South Korea, Nov. 9, 2021 /PRNewswire/ -- Global businesses and institutes are knocking on the door to the Hanmi Science Consortium having proprietary LNP technology. After Hanmi Science concluded a 'pandemic science alliance agreement' with the University of Oxford, increasingly more entities are joining the consortium to join hands to remove the so-called 'COVID-19 vaccine divide'. According to...
InnoCare to Present Orelabrutinib Data at the Upcoming 63rd Annual Meeting of ASH
BEIJING, Nov. 9, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company will present latest data of its BTK inhibitor orelabrutinib at the 63rd American Society of Hematology (ASH) Annual Meeting on December 11-14, 2021, which will be hold online and offline in Atlanta, Georgia. The study in patients with relapsed...
Recbio Announces New Study Showing Its COVID-19 Vaccine Induced High Levels of Neutralizing Antibodies against SARS-CoV-2 and Variants of Concern
TAIZHOU, China, Nov. 9, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. ("Recbio"), a biopharmaceutical company focusing on the research, development and commercialization of innovative vaccines that can address prevalent diseases with significant burden, today announced preclinical data from its ReCOV a recombinant trimeric NTD and RBD two-component SARS-CoV-2 subunit vaccine...
Sustained Hepatitis B Surface Antigen Loss in Chronic Hepatitis B Patients with Subcutaneous PD-L1 Antibody ASC22 Treatment: Interim Results of Phase IIb Study
HANGZHOU, China and SHAOXING, China, Nov. 9, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today that the interim results of 44 chronic hepatitis B (CHB) patients from a Phase IIb trial of ASC22 (Envafolimab), a subcutaneously administered PD-L1 antibody (ClinicalTrials.gov Identifier: NCT04465890), demonstrated sustained HBsAg loss in CHB patients with baseline HBsAg ≤ 500 IU/mL. The result abstract...
CStone Pharmaceuticals and DotBio sign a global discovery collaboration and option agreement to expand emerging portfolio of next-generation innovative therapeutics
The two sides will jointly develop up to three preclinical first-in-class or best-in-class next-generation antibody therapies, for which CStone would lead the design of the target combination based on the intended mechanism of action and DotBio will lead the design and engineering of the molecules CStone will take an equity position in DotBio, a biotech company specialized...
At 2021 Grand Challenges Annual Meeting, Bill & Melinda Gates Foundation Announces Initiatives to Support Cutting-Edge Science in Low- and Middle-Income Countries and Help End the COVID Crisis
The foundation commits initial $50 million towards a new 10-year program and awards science leadership fellowships to 14 African scientists SEATTLE, Nov. 9, 2021 /PRNewswire/ -- Today at the 17th Grand Challenges Annual Meeting, the Bill & Melinda Gates Foundation announced an initial commitment of $50 million to support science and innovation in low- and middle-income countries. The Grand Challenges...
Standigm Established a Synthetic Research Center to Improve Efficiency of AI Drug Discovery
SEOUL, South Korea, Nov. 8, 2021 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, announced today that the company had established a Synthetic Research Center in the headquarters of SK Chemicals Co., Ltd ("SK Chemicals", KRX 285130), a life science and green chemicals company. ...
Ascentage Pharma Announces Clinical Trial Agreement to Evaluate the Combination of Lisaftoclax (APG-2575) and the CDK4/6 Inhibitor IBRANCE® (Palbociclib) in Metastatic ER+/HER2- Breast Cancer
SUZHOU, China, and ROCKVILLE, Md., Nov. 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced a clinical trial collaboration and supply agreement with Pfizer Inc. to study the combination of Ascentage Pharma's...
VolitionRx Limited Schedules Third Quarter 2021 Earnings Conference Call and Business Update
AUSTIN, Texas, Nov. 8, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday, November 11, at 8:00 a.m. Eastern time to discuss its financial and operating results for the third quarter of 2021, in addition to providing a business update. Event: VolitionRx Limited Third Quarter 2021 Earnings and Business...
